VRAX

Virax Biolabs Group Ltd. (VRAX) | Rumor.io

Virax Biolabs Group

VRAX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,902

Bullish sentiment (50-day avg)63%

Price to earnings ratio-0.18

Market capitalization1.8M

Earnings per share-12.6

Dividend yield (TTM)—

Revenue (annual)12.4K

Net income (annual)-5M

Social

What share of all stock conversation is about VRAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 20

The company's low share count and trading at 50% below cash value make it a potential candidate for a significant price increase.
The company is well-positioned to benefit from the worsening Ebola outbreak, which is escalating to pandemic-emergency status.
The company has a live webinar scheduled on August 25 to discuss its immune diagnostics roadmap, which may contribute to a surge in its stock price.

Generated by AI

Sentiment

Of the messages about VRAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% new	30% -34.81	80.14% +9.86
Bearish	0%	0% -100	70% +34.81	19.86% -9.86

Bullish· Aug 19

$VRAX could be a $10+ stock today, driven by its momentum and increasing commercial traction.
The stock's momentum is heating up, with aggressive price action and millions of shares changing hands, indicating a strong potential for further growth.
$VRAX has a clear path to reaching new highs, with fair value per share estimated to be $7–$10, and potential for even higher prices based on commercial traction and stronger clinical validation.

Bearish· Aug 19

The price of VRAX plummeted from $4.29 to a low of $3.00, indicating a significant decline in value.
The stock is considered a "trash stock" by some investors, who view it as a potential "pump and dump" scheme or a "rug pull" opportunity.
The stock's price action is characterized by a "slap down" or a "smack down", suggesting a rapid and significant decline in value.

Generated by AI

Topics

Of the messages about VRAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	2.47%
Technical Analysis	—	—	33.33%	3.53%
Analysts	—	—	0%	46.93%
Controversies	—	—	0%	0.21%
Earnings	—	—	0%	0%
Macro	—	—	0%	46.87%

Announcements· Jul 9

Virax Biolabs Group Limited has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, granting Fosun exclusive distribution rights across Singapore, Thailand, Vietnam, Indonesia, and more.
The agreement is a significant distribution catalyst for Virax Biolabs, with the potential for commercial traction and revenue growth in the region.
Virax Biolabs has also exercised preferred investment options for $3.3 million in gross proceeds, which may impact the stock's structure and market reaction.

Technical Analysis· Jul 9

$VRAX is experiencing a potential squeeze, with insiders holding onto shares and a lack of offering risk.
The stock has formed a wedge setup, and a breakout above the critical 12.3 resistance level could trigger an explosive run to the 13+ zone.
Technical indicators, including the MACD and RSI, suggest a strong bullish momentum, with the potential for a run to $13 or higher.

Generated by AI

Community

Of the messages about VRAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	40%	55.56%	20.99%
Newcomers	66.67%	60%	44.44%	79.01%

Regulars· Aug 19

The price of VRAX is perking up, with some users expecting a potential break and base over the current pre-market supply, potentially leading to a higher price.
VRAX is a strong watch for today, with some users anticipating a "make or break" level, and others expecting a potential squeeze.
VRAX has been experiencing a low-float situation, which has been giving scalps opportunities to trade, but some users are also concerned about the risk of a rug pull.

Newcomers· Aug 19

Newcomers are speculating about the asset's potential price increase, with some predicting it could reach $7 to $10.
There is a significant increase in trader attention, with high volatility, heavy volume, and fast price action, suggesting a surge in interest.
The asset's price is experiencing a rapid decline, with some users attributing it to a "nasty sell off" and others calling it a "pump and dump" scheme.

Generated by AI

News

Virax Biolabs Expands ATM Share Offering With New SEC Filing

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

24d agoThe Globe and Mail

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program ...

1mo agoYahoo! Finance Canada

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Virax Biolabs reports $6.4m cash, regains Nasdaq compliance

2mo agoInvesting.com

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing context on the Company's fiscal 2026 Annual Report and subsequent commercial, financing and Nasdaq compliance developments.

2mo agoYahoo Finance

Also Discussed

Investors talking about VRAX also mention

#	Name	Attention
1	GeoVax Labs, Inc.GOVX	0%+0
2	Baiya International Group Inc. Class A Ordinary SharesBIYA	0%new
3	Maison Solutions Inc. Class A Common StockMSS	0%new
4	Hitek Global Inc.HKIT	0%0
5	Aethlon Medical, Inc.AEMD	0%new
6	MGAM - Mobile Global Esports Inc.	——
7	Quoin Pharmaceuticals, Ltd. American Depositary SharesQNRX	0%0
8	Intelligent Living Application Group Inc.ILAG	0%new
9	Russell Investments U.S. Small Cap Equity Active ETFRUSC	0%0
10	United Maritime CorporationUSEA	0%0

Virax Biolabs Group Ltd.

Healthcare
Biotechnology

Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases. Its core work centers on T cell-based in vitro diagnostic technologies and immunology profiling tools designed to help assess immune risk related to viral and immune-mediated conditions. The company develops and commercializes diagnostic test kits and related med-tech products under the ViraxClear brand, while its ViraxImmune platform is intended to support immune profiling and the evaluation of post-viral syndromes such as Long COVID and other chronic immune dysfunction states. Virax Biolabs Group Ltd. serves healthcare and research-oriented markets where viral detection, immune assessment, and diagnostic support are important, positioning the company within the broader biotechnology and in vitro diagnostics sectors. The company is headquartered in BioCity Glasgow, United Kingdom.

Website

Location

BioCity Glasgow

Lanarkshire, ML1 5UH

United Kingdom

Social

What share of all stock conversation is about VRAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Aug 20

The company's low share count and trading at 50% below cash value make it a potential candidate for a significant price increase.
The company is well-positioned to benefit from the worsening Ebola outbreak, which is escalating to pandemic-emergency status.
The company has a live webinar scheduled on August 25 to discuss its immune diagnostics roadmap, which may contribute to a surge in its stock price.

Generated by AI

Sentiment

Of the messages about VRAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% new	30% -34.81	80.14% +9.86
Bearish	0%	0% -100	70% +34.81	19.86% -9.86

Bullish· Aug 19

$VRAX could be a $10+ stock today, driven by its momentum and increasing commercial traction.
The stock's momentum is heating up, with aggressive price action and millions of shares changing hands, indicating a strong potential for further growth.
$VRAX has a clear path to reaching new highs, with fair value per share estimated to be $7–$10, and potential for even higher prices based on commercial traction and stronger clinical validation.

Bearish· Aug 19

The price of VRAX plummeted from $4.29 to a low of $3.00, indicating a significant decline in value.
The stock is considered a "trash stock" by some investors, who view it as a potential "pump and dump" scheme or a "rug pull" opportunity.
The stock's price action is characterized by a "slap down" or a "smack down", suggesting a rapid and significant decline in value.

Generated by AI

Topics

Of the messages about VRAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	2.47%
Technical Analysis	—	—	33.33%	3.53%
Analysts	—	—	0%	46.93%
Controversies	—	—	0%	0.21%
Earnings	—	—	0%	0%
Macro	—	—	0%	46.87%

Announcements· Jul 9

Virax Biolabs Group Limited has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, granting Fosun exclusive distribution rights across Singapore, Thailand, Vietnam, Indonesia, and more.
The agreement is a significant distribution catalyst for Virax Biolabs, with the potential for commercial traction and revenue growth in the region.
Virax Biolabs has also exercised preferred investment options for $3.3 million in gross proceeds, which may impact the stock's structure and market reaction.

Technical Analysis· Jul 9

$VRAX is experiencing a potential squeeze, with insiders holding onto shares and a lack of offering risk.
The stock has formed a wedge setup, and a breakout above the critical 12.3 resistance level could trigger an explosive run to the 13+ zone.
Technical indicators, including the MACD and RSI, suggest a strong bullish momentum, with the potential for a run to $13 or higher.

Generated by AI

Community

Of the messages about VRAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	40%	55.56%	20.99%
Newcomers	66.67%	60%	44.44%	79.01%

Regulars· Aug 19

The price of VRAX is perking up, with some users expecting a potential break and base over the current pre-market supply, potentially leading to a higher price.
VRAX is a strong watch for today, with some users anticipating a "make or break" level, and others expecting a potential squeeze.
VRAX has been experiencing a low-float situation, which has been giving scalps opportunities to trade, but some users are also concerned about the risk of a rug pull.

Newcomers· Aug 19

Newcomers are speculating about the asset's potential price increase, with some predicting it could reach $7 to $10.
There is a significant increase in trader attention, with high volatility, heavy volume, and fast price action, suggesting a surge in interest.
The asset's price is experiencing a rapid decline, with some users attributing it to a "nasty sell off" and others calling it a "pump and dump" scheme.

Generated by AI

Virax Biolabs Group

Social

Aug 20

Bullish· Aug 19

Bearish· Aug 19

Announcements· Jul 9

Technical Analysis· Jul 9

Regulars· Aug 19

Newcomers· Aug 19

Virax Biolabs Expands ATM Share Offering With New SEC Filing

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

Virax Biolabs reports $6.4m cash, regains Nasdaq compliance

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Also Discussed

Virax Biolabs Group Ltd.

Company Information

Location

Virax Biolabs Expands ATM Share Offering With New SEC Filing

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

Virax Biolabs reports $6.4m cash, regains Nasdaq compliance

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Also Discussed

Social

Aug 20

Bullish· Aug 19

Bearish· Aug 19

Announcements· Jul 9

Technical Analysis· Jul 9

Regulars· Aug 19

Newcomers· Aug 19